Towards Next Generation CAR Therapy Including In Vivo Programming of Immune Cells & Non-Oncology Indications

Time: 5:00 pm
day: Day Two


  • Development of first wave ex vivo manufactured autologous CAR-T cell products for B-cell malignancies yielded invaluable lessons, paving the way to next generation therapies
  • Key opportunities to expand the footprint of this treatment modality include design and development of transformative off-the-shelf therapies including in vivo CARs, as well as translation of this technology to non-oncology indications – both explored in this presentation